Incyte INCY
NASDAQ INCY
$127.85 -0.15 (-0.12%)
As of: Sep 4, 2026 · 2:42 PM EDT

Incyte (INCY) Non Operating Investment Income (2015 - 2026)

Incyte's (INCY) quarterly Non Operating Investment Income came in at $9.8 million in Q2 2026, up 336.21% YoY from $2.2 million in Q2 2025, and up 48.76% on a QoQ basis from $6.6 million in Q1 2026.

Analysis

Incyte (INCY) Non Operating Investment Income (2015 - 2026) Analysis & Trends

Incyte (INCY) has 7 years of Non Operating Investment Income data on file, last reported at $9.8 million in Q2 2026.

  • Quarterly Non Operating Investment Income rose 336.21% year-over-year to $9.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $43.2 million (up 250.75% YoY) and the FY2025 annual result came in at $21.3 million, down 81.63% from the prior year.
  • Non Operating Investment Income improved to $9.8 million in Q2 2026, from $6.6 million in the prior quarter.
  • In the past five years, Non Operating Investment Income ranged from a high of $99.9 million in Q1 2024 to a low of -$26.7 million in Q3 2023.
  • A 4-year average of $15.6 million and a median of $8.6 million in 2025 frame the typical range for Non Operating Investment Income.
  • Annual changes were most pronounced in 2024 — Non Operating Investment Income tumbled 129.9% — and 2026, when it jumped 590.77%.
  • Tracing INCY's Non Operating Investment Income over 4 years: stood at $34.1 million in 2023, then plunged by 129.9% to -$10.2 million in 2024, then surged by 279.22% to $18.2 million in 2025, then sank by 46.26% to $9.8 million in 2026.
  • The last three Non Operating Investment Income figures came in at $9.8 million (Q2 2026), $6.6 million (Q1 2026), and $18.2 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Vertex Pharmaceuticals 138.74 Bn 130.89 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.52 Bn 77.52 Bn 3.93 Bn -
3 Argenx Se 63.51 Bn 58.32 Bn 1.37 Bn -
4 Moderna 58.04 Bn 52.91 Bn 52.00 Mn -
5 Revolution Medicines 44.06 Bn 44.06 Bn - -
6 BeOne Medicines 39.98 Bn 34.88 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.46 Bn 32.15 Bn 992.69 Mn -
8 Royalty Pharma 28.41 Bn 27.57 Bn - -
9 Insmed 27.44 Bn 26.28 Bn 358.27 Mn -
10 Incyte 25.61 Bn 21.07 Bn 1.57 Bn 9.81 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 9.81 Mn
Mar 31, 2026 6.59 Mn
Dec 31, 2025 18.25 Mn
Sep 30, 2025 8.56 Mn
Jun 30, 2025 -4.15 Mn
Mar 31, 2025 -1.34 Mn
Dec 31, 2024 -10.18 Mn
Sep 30, 2024 -12.98 Mn
Jun 30, 2024 39.24 Mn
Mar 31, 2024 99.95 Mn
Dec 31, 2023 34.05 Mn
Sep 30, 2023 -26.65 Mn
Jun 30, 2023 41.81 Mn
Dec 31, 2017 -21.93 Mn
Sep 30, 2017 23.05 Mn
Jun 30, 2017 -19.57 Mn
Mar 31, 2017 -5.81 Mn
Dec 31, 2016 -23.76 Mn
Sep 30, 2016 24.30 Mn
Jun 30, 2016 -854,000.00